Progress and future opportunities in the development of vaccines against atherosclerosis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Review of Vaccines

• Publication date

  2017-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/14760584.2017.1258309PMID 27817213
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chlamydomonas reinhardtii chloroplasts express an orally immunogenic protein targeting the p210 epitope implicated in atherosclerosis immunotherapies

  2016cited by this paper
• ATRQ&bgr;-001 vaccine prevents atherosclerosis in apolipoprotein E-null mice

  2016cited by this paper
• Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.

  2015cited by this paper
• PCSK9 and its modulation.

  2015cited by this paper
• Mycobacterial heat shock protein 65 (mbHSP65)-induced atherosclerosis: Preventive oral tolerization and definition of atheroprotective and atherogenic mbHSP65 peptides.

  2015cited by this paper
• Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

  2015cited by this paper
• A cholesterol-lowering VLP vaccine that targets PCSK9.

  2015cited by this paper
• Bacillus subtilis comes of age as a vaccine production host and delivery vehicle

  2015cited by this paper
• Sublingual Vaccine with GroEL Attenuates Atherosclerosis

  2014cited by this paper
• CD8(+)CD25(+) T cells reduce atherosclerosis in apoE(-/-) mice.

  2014cited by this paper
• Immunological aspects of using plant cells as delivery vehicles for oral vaccines

  2014cited by this paper
• Transgenic plants: a 5-year update on oral antipathogen vaccine development

  2014cited by this paper
• Correction: Immunization of Chlamydia pneumoniae (Cpn)-Infected Apobtm2SgyLdlrtm1Her/J Mice with a Combined Peptide of Cpn Significantly Reduces Atherosclerotic Lesion Development

  2014cited by this paper
• Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management

  2014cited by this paper
• Regulatory T Cells as Immunotherapy

  2014cited by this paper
• A Vaccine Targeted at CETP Alleviates High Fat and High Cholesterol Diet-Induced Atherosclerosis and Non-Alcoholic Steatohepatitis in Rabbit

  2014cited by this paper
• Oral dosing with multi-antigenic construct induces atheroprotective immune tolerance to individual peptides in mice.

  2014cited by this paper
• Algae-based oral recombinant vaccines

  2014cited by this paper
• Impairment of Circulating CD4+CD25+GARP+ Regulatory T Cells in Patients with Acute Coronary Syndrome

  2014cited by this paper
• Recombinant protein expression in Escherichia coli: advances and challenges

  2014cited by this paper
• A role for impaired regulatory T cell function in adverse responses to aluminum adjuvant-containing vaccines in genetically susceptible individuals.

  2014cited by this paper
• Production of a Plant-Derived Immunogenic Protein Targeting ApoB100 and CETP: Toward a Plant-Based Atherosclerosis Vaccine

  2014cited by this paper
• Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100

  2013cited by this paper
• Decreased numbers of regulatory T cells are associated with human atherosclerotic lesion vulnerability and inversely correlate with infiltrated mature dendritic cells.

  2013cited by this paper
• Immune responses elicited by apoB-100-derived peptides in mice

  2013cited by this paper
• Vaccines against atherosclerosis

  2013cited by this paper
• Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.

  2013cited by this paper
• Next‐generation peptide vaccines for advanced cancer

  2013cited by this paper
• A perspective for atherosclerosis vaccination: is there a place for plant-based vaccines?

  2013cited by this paper
• Pathophysiology of atherosclerosis plaque progression.

  2013cited by this paper
• Active immunotherapy for chronic diseases.

  2013cited by this paper
• C-Reactive Protein, but not Low-Density Lipoprotein Cholesterol Levels, Associate With Coronary Atheroma Regression and Cardiovascular Events After Maximally Intensive Statin Therapy

  2013cited by this paper
• Immunization of Chlamydia pneumoniae (Cpn)-Infected Apobtm2SgyLdlrtm1Her/J Mice with a Combined Peptide of Cpn Significantly Reduces Atherosclerotic Lesion Development

  2013cited by this paper
• Engineering lactococci and lactobacilli for human health.

  2013cited by this paper
• Mucosal Tolerance to a Combination of ApoB and HSP60 Peptides Controls Plaque Progression and Stabilizes Vulnerable Plaque in Apobtm2SgyLdlrtm1Her/J Mice

  2013cited by this paper
• Effects of dalcetrapib in patients with a recent acute coronary syndrome.

  2012cited by this paper
• Regulatory T cells in atherogenesis.

  2012cited by this paper
• Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.

  2012cited by this paper
• Subcutaneous immunization with heat shock protein-65 reduces atherosclerosis in Apoe⁻/⁻ mice.

  2012cited by this paper
• CD8+ T Cells Mediate the Athero-Protective Effect of Immunization with an ApoB-100 Peptide

  2012cited by this paper
• Bacillus subtilis

  2012cited by this paper
• Effects of nasal immunization of multi-target preventive vaccines on atherosclerosis.

  2012cited by this paper
• Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia

  2012cited by this paper
• Regulatory T-Cell Response to Apolipoprotein B100–Derived Peptides Reduces the Development and Progression of Atherosclerosis in Mice

  2012cited by this paper
• Impact of multiple antigenic epitopes from ApoB100, hHSP60 and Chlamydophila pneumoniae on atherosclerotic lesion development in Apob(tm2Sgy)Ldlr(tm1Her)J mice.

  2012cited by this paper
• Dendritic cells and regulatory T cells in atherosclerosis

  2012cited by this paper
• Can a plant-based vaccine treat hypertension?

  2012cited by this paper
• Oral administration of myostatin-specific whole recombinant yeast Saccharomyces cerevisiae vaccine increases body weight and muscle composition in mice.

  2011cited by this paper
• Regulatory T cells: stability revisited.

  2011cited by this paper
• Regulatory T Cells

  2011cited by this paper
• Evidence for a role of regulatory T cells in mediating the atheroprotective effect of apolipoprotein B peptide vaccine

  2011cited by this paper
• Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.

  2011cited by this paper
• A chimeric peptide of intestinal trefoil factor containing cholesteryl ester transfer protein B cell epitope significantly inhibits atherosclerosis in rabbits after oral administration.

  2011cited by this paper
• Immunization of apoE-/- mice with aldehyde-modified fibronectin inhibits the development of atherosclerosis.

  2011cited by this paper
• Therapeutic vaccines for chronic diseases: successes and technical challenges

  2011cited by this paper
• Oral administration of Lactococcus lactis delivered heat shock protein 65 attenuates atherosclerosis in low-density lipoprotein receptor-deficient mice.

  2011cited by this paper
• Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis

  2010cited by this paper
• Intranasal Immunization With an Apolipoprotein B-100 Fusion Protein Induces Antigen-Specific Regulatory T Cells and Reduces Atherosclerosis

  2010cited by this paper
• Immune responses against fibronectin modified by lipoprotein oxidation and their association with cardiovascular disease

  2009cited by this paper
• Mechanisms of foxp3+ T regulatory cell-mediated suppression.

  2009cited by this paper
• Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

  2009cited by this paper
• How regulatory T cells work

  2008cited by this paper
• The Proprotein Convertase PCSK9 Induces the Degradation of Low Density Lipoprotein Receptor (LDLR) and Its Closest Family Members VLDLR and ApoER2*

  2008cited by this paper
• Intranasal immunization with chitosan/pCETP nanoparticles inhibits atherosclerosis in a rabbit model of atherosclerosis.

  2008cited by this paper
• Treatment with apo B peptide vaccines inhibits atherosclerosis in human apo B‐100 transgenic mice without inducing an increase in peptide‐specific antibodies

  2008cited by this paper
• High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction.

  2008influential reference
• Genome‑based vaccine development: A short cut for the future

  2008cited by this paper
• The Th17/Treg imbalance in patients with acute coronary syndrome.

  2008cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• Effect of torcetrapib on the progression of coronary atherosclerosis.

  2007cited by this paper
• Regulatory T cells – a brief history and perspective

  2007cited by this paper
• Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events.

  2007influential reference
• Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.

  2007cited by this paper
• Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia

  2007cited by this paper
• Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation*

  2007influential reference
• Effects of torcetrapib in patients at high risk for coronary events.

  2007influential reference
• Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.

  2007cited by this paper
• Natural regulatory T cells control the development of atherosclerosis in mice

  2006cited by this paper
• Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis.

  2006cited by this paper
• Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes.

  2006cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Mechanisms of suppression by suppressor T cells

  2005cited by this paper
• Immunization using an Apo B-100 related epitope reduces atherosclerosis and plaque inflammation in hypercholesterolemic apo E (-/-) mice.

  2005cited by this paper
• Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model.

  2005cited by this paper
• Vaccinating Rabbits with a Cholesteryl Ester Transfer Protein (CETP) B-Cell Epitope Carried by Heat Shock Protein-65 (HSP65) for Inducing Anti-CETP Antibodies and Reducing Aortic Lesions In Vivo

  2005cited by this paper
• Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice

  2005cited by this paper
• Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

  2005cited by this paper
• Mechanisms of suppression by suppressor T cells

  2005cited by this paper
• Expressing and purifying an anti-atherosclerosis polypeptide vaccine in Escherichia coli.

  2004cited by this paper
• Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-amino acid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants.

  2004cited by this paper
• Recombinant Human Antibodies Against Aldehyde-Modified Apolipoprotein B-100 Peptide Sequences Inhibit Atherosclerosis

  2004cited by this paper
• Atheroprotective immunization with MDA-modified apo B-100 peptide sequences is associated with activation of Th2 specific antibody expression.

  2004cited by this paper
• Control of autoimmunity by naturally arising regulatory CD4+ T cells.

  2003cited by this paper
• Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

  2003cited by this paper
• Identification of Immune Responses Against Aldehyde-Modified Peptide Sequences in ApoB Associated With Cardiovascular Disease

  2003cited by this paper
• The safety and immunogenicity of a CETP vaccine in healthy adults.

  2003cited by this paper
• Foot-and-mouth disease virus VP1 protein fused with cholera toxin B subunit expressed in Chlamydomonas reinhardtii chloroplast

  2003cited by this paper
• Inhibition of Atherosclerosis in ApoE-Null Mice by Immunization with ApoB-100 Peptide Sequences

  2003cited by this paper
• Characterization of a naturally occurring new version of the cholesterol ester transfer protein (CETP) from small intestine

  2003cited by this paper
• New mouse models for lipoprotein metabolism and atherosclerosis

  2002cited by this paper

• Immunology of atherosclerosis: problems and prospects of immunotherapy

  2025cites this paper
• Multi-omics analysis reveals overactive inflammation and dysregulated metabolism in severe community-acquired pneumonia patients

  2024cites this paper
• Diabetic vascular diseases: molecular mechanisms and therapeutic strategies

  2023cites this paper
• Engineering a novel immunogenic chimera protein utilizing bacterial infections associated with atherosclerosis to induce a deviation in adaptive immune responses via Immunoinformatics approaches.

  2022cites this paper
• PCSK9 Biomarker and Key Modulator for Cardiovascular Disorders: Heralding a New Therapeutic Era and their Future Perspectives.

  2022cites this paper
• Structure and function of proprotein convertase subtilisin/kexin type 9 (PCSK9) in atherosclerosis.

  2019cites this paper
• Role of PCSK9 in lipid metabolism and atherosclerosis.

  2018cites this paper
• The quest for immunotherapy in atherosclerosis: CANTOS study, interleukin-1β and vascular inflammation.

  2018cites this paper
• Statins reduce the expressions of Tim‐3 on NK cells and NKT cells in atherosclerosis

  2018cites this paper
• Heat shock proteins and cardiovascular disease.

  2018cites this paper
• Enhanced Antiatherosclerotic Efficacy of Statin-Loaded Reconstituted High-Density Lipoprotein via Ganglioside GM1 Modification.

  2018cites this paper
• Vaccine against PCSK9: the natural strategy from passive to active immunization for the prevention of atherosclerosis.

  2017cites this paper
• Assessment of Carrot Callus as Biofactories of an Atherosclerosis Oral Vaccine Prototype

  2017cites this paper